HK1251567A1 - 用於激酶抑制的杂芳基化合物 - Google Patents
用於激酶抑制的杂芳基化合物 Download PDFInfo
- Publication number
- HK1251567A1 HK1251567A1 HK18111064.8A HK18111064A HK1251567A1 HK 1251567 A1 HK1251567 A1 HK 1251567A1 HK 18111064 A HK18111064 A HK 18111064A HK 1251567 A1 HK1251567 A1 HK 1251567A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- kinase inhibition
- heteroaryl compounds
- compounds
- mutant
- kinase activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562160989P | 2015-05-13 | 2015-05-13 | |
| US201562160989P | 2015-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1251567A1 true HK1251567A1 (zh) | 2019-02-01 |
Family
ID=57249337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18111064.8A HK1251567A1 (zh) | 2015-05-13 | 2016-05-12 | 用於激酶抑制的杂芳基化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210323976A1 (https=) |
| EP (1) | EP3294712A4 (https=) |
| JP (1) | JP6863901B2 (https=) |
| HK (1) | HK1251567A1 (https=) |
| WO (1) | WO2016183278A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| TWI726968B (zh) | 2016-01-07 | 2021-05-11 | 開曼群島商Ｃｓ醫藥技術公司 | Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑 |
| CN108299419B (zh) * | 2017-01-11 | 2022-04-26 | 南京圣和药业股份有限公司 | 一种新型egfr激酶抑制剂的几种新晶型及其制备方法 |
| CN109705118B (zh) * | 2017-10-25 | 2021-12-28 | 南京圣和药业股份有限公司 | 三环类egfr激酶抑制剂的制备方法 |
| CN109705117A (zh) * | 2017-10-25 | 2019-05-03 | 南京圣和药业股份有限公司 | 三环类化合物、其制备方法及用途 |
| CN108191861B (zh) * | 2018-03-01 | 2020-10-02 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺 |
| CA3143919A1 (en) * | 2019-06-20 | 2020-12-24 | Oncobix Co., Ltd. | Pyrimidine derivative inhibiting growth of cancer cell and medicinal use thereof |
| EP4100409B1 (en) | 2020-02-03 | 2024-08-28 | Boehringer Ingelheim International GmbH | [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors |
| JP7626774B2 (ja) * | 2020-02-03 | 2025-02-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| CN112409192A (zh) * | 2020-11-26 | 2021-02-26 | 启东东岳药业有限公司 | 一种4-氟-2-甲氧基苯胺的纯化方法 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960572B2 (en) * | 2001-06-21 | 2005-11-01 | Ariad Pharmaceuticals, Inc. | Indolinones and uses thereof |
| TWI552752B (zh) * | 2007-10-19 | 2016-10-11 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| MX353308B (es) * | 2008-05-21 | 2018-01-08 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| US9273077B2 (en) * | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| NZ603525A (en) * | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| EP4119551A1 (en) * | 2011-07-27 | 2023-01-18 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
| CA2927924A1 (en) * | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| JP6468611B2 (ja) * | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| EP3778584A1 (en) * | 2014-06-19 | 2021-02-17 | ARIAD Pharmaceuticals, Inc. | Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives |
| CA2984586C (en) * | 2015-04-29 | 2021-02-16 | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor |
-
2016
- 2016-05-12 EP EP16793497.5A patent/EP3294712A4/en not_active Withdrawn
- 2016-05-12 US US15/573,211 patent/US20210323976A1/en not_active Abandoned
- 2016-05-12 HK HK18111064.8A patent/HK1251567A1/zh unknown
- 2016-05-12 JP JP2017558660A patent/JP6863901B2/ja not_active Expired - Fee Related
- 2016-05-12 WO PCT/US2016/031996 patent/WO2016183278A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20210323976A1 (en) | 2021-10-21 |
| EP3294712A4 (en) | 2018-11-07 |
| WO2016183278A1 (en) | 2016-11-17 |
| JP2018515514A (ja) | 2018-06-14 |
| EP3294712A1 (en) | 2018-03-21 |
| JP6863901B2 (ja) | 2021-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY186839A (en) | Heteroaryl compounds for kinase inhibition | |
| HK1251567A1 (zh) | 用於激酶抑制的杂芳基化合物 | |
| ZA201801724B (en) | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same | |
| EP3484504A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE | |
| EP3340981A4 (en) | ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISEASES | |
| LT3604294T (lt) | Junginiai ir kompozicijos, skirti egfr mutantinės kinazės veiklos moduliavimui | |
| PH12016501898B1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
| PH12016500582B1 (en) | Heterocyclic compounds and uses thereof | |
| PH12016501809A1 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| PH12021550413A1 (en) | Vitamin d pediatric dosage forms, methods of making and using | |
| EP3394047A4 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| AU2017248276A1 (en) | Methods of treating ocular conditions | |
| EP3192875A4 (en) | Sustained-release pharmaceutical composition for treating and preventing ophthalmic diseases | |
| EP4339192A3 (en) | Compounds and compositions for the treatment of cancer | |
| EP3831365A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ATOPIC DISEASES | |
| EP3388514A4 (en) | Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases | |
| WO2014110198A3 (en) | Therapeutic indications of kinase inhibitors | |
| HK1249756A1 (zh) | 用於治疗疾病的稠合双环化合物 | |
| WO2015145388A3 (en) | Methods of treating colorectal cancers harboring upstream wnt pathway mutations | |
| EP3267992A4 (en) | Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases | |
| NZ763986A (en) | Heteroaryl compounds for kinase inhibition | |
| TH1601007484A (th) | สารประกอบเฮเทอโรแอริลสำหรับการยับยั้งไคเนส | |
| MX2019014773A (es) | Inhibidores de ccl2. | |
| HK1247584A1 (zh) | 結晶c21h22c12n4o2丙二酸酯 | |
| HK1227849A1 (en) | Heterocyclic compounds and uses thereof |